Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

Jacqueline Vuky, Christina Isacson, Mehran Fotoohi, Jason Dela Cruz, Henry Otero, Vincent Picozzi, Thomas Malpass, David Aboulafia, Andrew Jacobs

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalInvestigational New Drugs
Volume24
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Karnofsky Performance Status
Life Expectancy
Nausea
Renal Insufficiency
Neoplasms
Immunohistochemistry
Kidney
Imatinib Mesylate
Liver
Proteins

Keywords

  • Imatinib (Gleevec®)
  • Metastatic renal cell carcinoma
  • Phase II trial

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Vuky, J., Isacson, C., Fotoohi, M., Dela Cruz, J., Otero, H., Picozzi, V., ... Jacobs, A. (2006). Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma. Investigational New Drugs, 24(1), 85-88. https://doi.org/10.1007/s10637-005-4543-z

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma. / Vuky, Jacqueline; Isacson, Christina; Fotoohi, Mehran; Dela Cruz, Jason; Otero, Henry; Picozzi, Vincent; Malpass, Thomas; Aboulafia, David; Jacobs, Andrew.

In: Investigational New Drugs, Vol. 24, No. 1, 01.2006, p. 85-88.

Research output: Contribution to journalArticle

Vuky, J, Isacson, C, Fotoohi, M, Dela Cruz, J, Otero, H, Picozzi, V, Malpass, T, Aboulafia, D & Jacobs, A 2006, 'Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma', Investigational New Drugs, vol. 24, no. 1, pp. 85-88. https://doi.org/10.1007/s10637-005-4543-z
Vuky, Jacqueline ; Isacson, Christina ; Fotoohi, Mehran ; Dela Cruz, Jason ; Otero, Henry ; Picozzi, Vincent ; Malpass, Thomas ; Aboulafia, David ; Jacobs, Andrew. / Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma. In: Investigational New Drugs. 2006 ; Vol. 24, No. 1. pp. 85-88.
@article{23d2fda22db74c77b3fe3505db03cc4d,
title = "Phase II trial of imatinib (Gleevec{\circledR}) in patients with metastatic renal cell carcinoma",
abstract = "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70{\%}, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28{\%}) and Grade II renal insufficiency (14{\%}). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7{\%}) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.",
keywords = "Imatinib (Gleevec{\circledR}), Metastatic renal cell carcinoma, Phase II trial",
author = "Jacqueline Vuky and Christina Isacson and Mehran Fotoohi and {Dela Cruz}, Jason and Henry Otero and Vincent Picozzi and Thomas Malpass and David Aboulafia and Andrew Jacobs",
year = "2006",
month = "1",
doi = "10.1007/s10637-005-4543-z",
language = "English (US)",
volume = "24",
pages = "85--88",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

AU - Vuky, Jacqueline

AU - Isacson, Christina

AU - Fotoohi, Mehran

AU - Dela Cruz, Jason

AU - Otero, Henry

AU - Picozzi, Vincent

AU - Malpass, Thomas

AU - Aboulafia, David

AU - Jacobs, Andrew

PY - 2006/1

Y1 - 2006/1

N2 - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.

AB - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.

KW - Imatinib (Gleevec®)

KW - Metastatic renal cell carcinoma

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=31544474604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544474604&partnerID=8YFLogxK

U2 - 10.1007/s10637-005-4543-z

DO - 10.1007/s10637-005-4543-z

M3 - Article

VL - 24

SP - 85

EP - 88

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -